Judy Li, PhD

AstraZeneca

Dr. Judy Li, PhD, is the Head of Hematology Strategy Oncology Statistics at AstraZeneca, where she provides leadership and expertise in hematology oncology statistics. With a keen focus on strategic planning, technical oversight, functional development, and operational guidance, Dr. Li plays a pivotal role in propelling the field of hematology statistics forward.

Throughout her career, Dr. Li has held senior leadership positions in both the biopharmaceutical and biotech sectors, making significant contributions at organizations including Bristol Myers Squibb, Celgene, and Regeneron Pharmaceuticals. Prior to her industry tenure, she garnered extensive experience at the US Food and Drug Administration (FDA) as a master statistical reviewer and supervisory mathematical statistician.

An esteemed member of the American Statistical Association (ASA) Biopharmaceutical Section Executive Board, Dr. Li is also the co-founder of the ASA Biopharmaceutical Safety Working Group and has previously chaired the Biopharmaceutical Section Regulatory Industry Statistics Workshop. She is the editor of book Quantitative Methodologies and Process for Safety Monitoring and Ongoing Benefit Risk Evaluation. Her remarkable contributions have been acknowledged with the FDA Office of Chief Scientist Intramural Grant Award for two consecutive years.

Dr. Li received her PhD in Statistics from the University of California, Riverside. Her unwavering dedication to advancing innovative statistical methodologies in the healthcare arena underscores her commitment to enhancing patient outcomes and furthering scientific understanding.